Emmaus Life Sciences IncOTCQB:EMMA
- LAST PRICE0.0499
- TODAY'S CHANGE (%)0.0228 (84.1328%)
- Bid / Lots0.0281/ 900
- Ask / Lots0.0499/ 100
- Open / Previous Close0.0324 / 0.0271
- Day Range
- 52 Week Range
- Volume3,270
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EMMA |
|---|---|---|
| 01:06 ET | 3250 | 0.0499 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Emmaus Life Sciences Inc | 1.7M | -0.6x | --- |
Predictive Technology Group Inc | 59.9K | 0.0x | --- |
Nabriva Therapeutics PLC | 970.0 | 0.0x | --- |
SQZ Biotechnologies Co | 678.3K | 0.0x | --- |
Equillium Inc | 26.6M | -3.1x | --- |
Cara Therapeutics Inc | 16.0M | -0.1x | --- |
Company Information
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The Company has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.
Contact Information
- Headquarters
- 21250 HAWTHORNE BOULEVARD, SUITE 800TORRANCE, CA, United States 90503
- Phone
- 310-214-0065
- Fax
- 310-214-0075
Executives
- Chairman of the Board, Chief Executive Officer, Chief Operating Officer
- Willis Lee
- Chief Financial Officer
- Yasushi Nagasaki
- Senior Vice President - Medical Affairs, Clinical, Regulatory
- Charles Stark
- Director
- Jon Kuwahara
- Independent Director
- Seah Lim
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7M |
|---|---|
Revenue (TTM) | $20.0M |
Shares Outstanding | 63.9M |
Emmaus Life Sciences Inc does not pay a dividend. | |
Beta | 6.96 |
EPS | $-0.08 |
Book Value | $-0.77 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
